Ampholyte Biomaterials Resolving Biocompatibility and Strength Trade-off
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomaterials for medical devices face challenges with biocompatibility, mechanical strength, and functionality, particularly in contact lenses and blood-contacting devices, where existing polymers either lack biocompatibility or mechanical strength.
Innovation Solution
Development of synthetic polymeric ampholyte biomaterials mimicking natural cell membrane components, such as 2-((2-hydroxyethyl)dimethylammonio)ethyl hydrogen phosphate, which exhibit high biocompatibility, haemocompatibility, and hydrophilicity, and can be integrated into or grafted onto various polymer backbones to enhance properties like mechanical strength, non-thrombogenicity, and drug delivery capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural hydrophilic polymers (collagen, alginates, hyaluronic acid) are used, then biocompatibility is improved, but mechanical strength deteriorates
Solution Approach 1:
The patent creates composite materials by integrating ampholyte compounds with synthetic polymer backbones (polycarbonates, polyesters, polyurethanes, polysiloxanes). This combination allows the material to exhibit both the biocompatibility of natural polymers and the mechanical strength of synthetic polymers, resolving the contradiction between these two properties.
2Strength
If artificially synthesized polymers (polyesters, polyethers, polycarbonates) are used, then mechanical strength is improved, but biocompatibility deteriorates
Solution Approach 1:
The patent applies local quality by incorporating ampholyte compounds at specific locations within the polymer structure (as pendant groups, side chains, or crosslinking agents). This localized modification of synthetic polymer backbones with biocompatible functional groups enables the material to maintain high mechanical strength while acquiring improved biocompatibility where it contacts biological systems.
3Reliability
If phospholipid compounds are polymerized, then biocompatibility is improved, but mechanical strength and processability deteriorate
Solution Approach 1:
The patent inverts the conventional approach by not polymerizing phospholipid compounds directly, but rather integrating them as ampholyte compounds into pre-formed synthetic polymer backbones. This reversal of the synthesis sequence allows the robust synthetic backbone to provide mechanical strength and processability, while the integrated phospholipid-derived ampholyte groups provide biocompatibility.
Data Source
AI summary
New ampholyte biomaterial compounds containing ampholyte moieties are synthesized and integrated into polymeric assemblies to provide hydrophilic polymers exhibiting improved biocompatibility, haemocompatibiiity, hydrophihcity non-thrombogenicity, anti-bacterial ability, and mechanical strength, as well as suitability as a drug delivery platform